Cyclerion’s olinciguat flunks sickle cell test; Nimbus nets $60M; Dyno-Roche’s gene therapy pact; RayzeBio debuts with $ 45M to target tumors
Oct 15, 2020
Cyclerion flunks sickle cell test, prompting pivot to CNS disease Cyclerion Therapeutics has terminated the development of olinciguat in sickle cell disease after getting a...
Read More
J&J ‘s COVID-19 vaccine; Roche, AC Immune’s anti-Tau Alzheimer’s drug; Silverback nets $85 M; Anokion’s deal rides out BMS-Celgene merger; Coronavirus spike protein could inspire vaccine development
Oct 1, 2020
J&J commences COVID-19 vaccine phase 3 Johnson & Johnson has begun a 60,000-subject phase 3 evaluation of its COVID-19 vaccine. The trial will enroll participants i...
Read More
Lilly’s COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian’s CD40L cell therapy
Oct 1, 2020
Lilly links COVID-19 antibody to a reduce hospitalization rate Eli Lilly has linked its anti-SARS-CoV-2 antibody to a lower rate of hospitalization in patients lately diagn...
Read More
Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates
Oct 1, 2020
Pfizer, BioNTech report shows the immune response in animals to COVID-19 Pfizer and its partner BioNTech have five potential COVID-19 vaccines in clinical trials, eac...
Read More
Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK’s COVID-19 monoclonal antibody therapy; AstraZeneca’s Farxiga scores goal in Phase III CDK trial
Oct 1, 2020
Nestle acquires peanut allergy treatment with USD 2 Billion Aimmune buyout Nestle has announced a definitive agreement to extend its acquisition of Aimmune Therapeutics. Ne...
Read More
FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes
Oct 1, 2020
FDA rejects BioMarin’s gene therapy and Gilead’s filgotinib over concerns The FDA refused to approve BioMarin’s hemophilia A gene therapy valoctocogene ro...
Read More
Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures
Oct 1, 2020
Roche bets USD 120 Million on UCB’s anti-tau Alzheimer’s antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB’s ...
Read More
Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates
Oct 1, 2020
Sanofi licenses NK cells of Kiadis to boost the efficacy Sanofi has licensed the natural killer (NK) cells from Kiadis Pharma for use in combination with its multiple...
Read More
Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva’s Yselty top-line studies
Oct 1, 2020
Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19. Regeneron is running two trials simultaneously, one fo...
Read More
FDA’s No to Intercept’s NASH Drug; Roche’s Phesgo gets approval; Gilead’s Remdesivir pricing
Oct 1, 2020
Intercept Pharmaceuticals receives a clear rejection from the FDA for its NASH drug, Obeticholic acid (OCA) Intercept Pharmaceuticals announced the issuance of a Complete R...
Read More
Regeneron’s I-O Drug; Gene Therapy for Parkinson’s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M
Oct 1, 2020
Regeneron recognizes new combos to boost I-O drug Libtayo’s cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patien...
Read More
Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114’s Phase III result
Oct 1, 2020
Sarepta Therapeutics has announced a research and option alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases T...
Read More
Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab’s result; Orca raises $192M
Oct 7, 2020
Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and...
Read More
Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost
Oct 1, 2020
Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 b...
Read More
In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit
Oct 1, 2020
Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients. The company plans to explore the anti-inflammatory ...
Read More
